Unraveling the Place of Small Molecules in theTreatment of Fistulizing Crohn’s Disease—A Systematic Review and Network Meta-Analysis

Mohamed Attauabi; Ditlev Nytoft Rasmussen; Fredrik Olof Bergenheim; Johan Burisch; Jakob Benedict Seidelin

doi:10.1093/crocol/otad074

Unraveling the Place of Small Molecules in theTreatment of Fistulizing Crohn’s Disease—A Systematic Review and Network Meta-Analysis

Mohamed Attauabi, Ditlev Nytoft Rasmussen, Fredrik Olof Bergenheim, Johan Burisch, Jakob Benedict Seidelin

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

22 Downloads (Pure)

Originalsprog	Engelsk
Artikelnummer	otad074
Tidsskrift	Crohn's and Colitis 360
Vol/bind	5
Udgave nummer	4
Antal sider	2
DOI	https://doi.org/10.1093/crocol/otad074
Status	Udgivet - 2023

Bibliografisk note

Funding Information:
M.A., D.N.R., and F.O.B report no conflicts of interest. J.B. reports grants and personal fees from AbbVie, grants and personal fees from Janssen-Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants, and personal fees from Bristol Myers Squibb, grants from Novo Nordisk, personal fees from Pharmacosmos, personal fees from Ferring, personal fees from Galapagos, outside the submitted work. J.B.S. has received research grants from Takeda, Janssen and is the national coordinator of studies from AbbVie, Arena Pharmaceuticals, Ely Lilly, and Boehringer Ingelheim. None of these pertain to the research submitted here.

Adgang til dokumentet

10.1093/crocol/otad074Licens: CC BY

FulltextForlagets udgivne version, 144 KBLicens: CC BY

Citationsformater

@article{9e96dca63d1f4b99858e89a91a65662e,

title = "Unraveling the Place of Small Molecules in theTreatment of Fistulizing Crohn{\textquoteright}s Disease—A Systematic Review and Network Meta-Analysis",

author = "Mohamed Attauabi and Rasmussen, {Ditlev Nytoft} and Bergenheim, {Fredrik Olof} and Johan Burisch and Seidelin, {Jakob Benedict}",

note = "Funding Information: M.A., D.N.R., and F.O.B report no conflicts of interest. J.B. reports grants and personal fees from AbbVie, grants and personal fees from Janssen-Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants, and personal fees from Bristol Myers Squibb, grants from Novo Nordisk, personal fees from Pharmacosmos, personal fees from Ferring, personal fees from Galapagos, outside the submitted work. J.B.S. has received research grants from Takeda, Janssen and is the national coordinator of studies from AbbVie, Arena Pharmaceuticals, Ely Lilly, and Boehringer Ingelheim. None of these pertain to the research submitted here. ",

year = "2023",

doi = "10.1093/crocol/otad074",

language = "English",

volume = "5",

journal = "Crohn's and Colitis 360",

issn = "2631-827X",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Unraveling the Place of Small Molecules in theTreatment of Fistulizing Crohn’s Disease—A Systematic Review and Network Meta-Analysis

AU - Attauabi, Mohamed

AU - Rasmussen, Ditlev Nytoft

AU - Bergenheim, Fredrik Olof

AU - Burisch, Johan

AU - Seidelin, Jakob Benedict

N1 - Funding Information: M.A., D.N.R., and F.O.B report no conflicts of interest. J.B. reports grants and personal fees from AbbVie, grants and personal fees from Janssen-Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants, and personal fees from Bristol Myers Squibb, grants from Novo Nordisk, personal fees from Pharmacosmos, personal fees from Ferring, personal fees from Galapagos, outside the submitted work. J.B.S. has received research grants from Takeda, Janssen and is the national coordinator of studies from AbbVie, Arena Pharmaceuticals, Ely Lilly, and Boehringer Ingelheim. None of these pertain to the research submitted here.

PY - 2023

Y1 - 2023

U2 - 10.1093/crocol/otad074

DO - 10.1093/crocol/otad074

M3 - Comment/debate

C2 - 38130950

AN - SCOPUS:85184750450

SN - 2631-827X

VL - 5

JO - Crohn's and Colitis 360

JF - Crohn's and Colitis 360

IS - 4

M1 - otad074

ER -